<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38825753</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>Fluvoxamine and long COVID: Post-acute recovery.</ArticleTitle><Pagination><StartPage>e2557</StartPage><MedlinePgn>e2557</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.2557</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reiersen</LastName><ForeName>Angela M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0003-3203-4590</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zorumski</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenze</LastName><ForeName>Eric J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Center for Brain Research in Mood Disorders at Washington University</Agency><Country/></Grant><Grant><Agency>The Bantly Foundation</Agency><Country/></Grant><Grant><GrantID>UL1TR002345</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>COVID-19 Early Treatment Fund</Agency><Country/></Grant><Grant><Agency>Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine in St. Louis</Agency><Country/></Grant><Grant><Agency>Washington University Institute of Clinical and Translational Sciences</Agency><Country/></Grant><Grant><GrantID>UL1 TR002345</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Cures Within Reach</Agency><Country/></Grant><Grant><Agency>Mercatus Fast Grants</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O4L1XPO44W</RegistryNumber><NameOfSubstance UI="D016666">Fluvoxamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Selective Serotonin Reuptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016666" MajorTopicYN="Y">Fluvoxamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>0</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38825753</ArticleId><ArticleId IdType="doi">10.1002/rmv.2557</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>The Lancet Infectious Diseases (editorial). Where are the long COVID trials? Lancet Infect Dis. 2023;23(8):879. https://doi.org/10.1016/s1473&#x2010;3099(23)00440&#x2010;1</Citation></Reference><Reference><Citation>Deng J, Moskalyk M, Zuo QK, et&#xa0;al. Evaluating fluvoxamine for the outpatient treatment of COVID&#x2010;19: a systematic review and meta&#x2010;analysis. Rev Med Virol. 2024;34(1):e2501. https://doi.org/10.1002/rmv.2501</Citation></Reference><Reference><Citation>Sukhatme VP, Reiersen AM, Vayttaden SJ, Sukhatme VV. Fluvoxamine: a review of its mechanism of action and its role in COVID&#x2010;19. Front Pharmacol. 2021;12:652688. https://doi.org/10.3389/fphar.2021.652688</Citation></Reference><Reference><Citation>Lenze EJ, Mattar C, Zorumski CF, et&#xa0;al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID&#x2010;19: a randomized clinical trial. JAMA. 2020;324(22):2292&#x2010;2300. https://doi.org/10.1001/jama.2020.22760</Citation></Reference><Reference><Citation>Reiersen AM, Mattar C, Bender Ignacio RA, et&#xa0;al. The STOP COVID 2 study: fluvoxamine vs placebo for outpatients with symptomatic COVID&#x2010;19, a fully remote randomized controlled trial. Open Forum Infect Dis. 2023;10(8):ofad419. https://doi.org/10.1093/ofid/ofad419</Citation></Reference><Reference><Citation>Rodebaugh TL, Frumkin MR, Reiersen AM, et&#xa0;al. Acute symptoms of mild to moderate COVID&#x2010;19 are highly heterogeneous across individuals and over time. Open Forum Infect Dis. 2021;8(3):ofab090. https://doi.org/10.1093/ofid/ofab090</Citation></Reference><Reference><Citation>Rosen DA, Seki SM, Fern&#xe1;ndez&#x2010;Casta&#xf1;eda A, et&#xa0;al. Modulation of the sigma&#x2010;1 receptor&#x2010;IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. Sci Transl Med. 2019;11(478):eaau5266. https://doi.org/10.1126/scitranslmed.aau5266</Citation></Reference><Reference><Citation>Hoertel N, S&#xe1;nchez&#x2010;Rico M, Gulbins E, et&#xa0;al. Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID&#x2010;19: an observational multicenter study. Clin Pharmacol Ther. 2021;110(6):1498&#x2010;1511. https://doi.org/10.1002/cpt.2317</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>